An Overview of Modern Strategies for Treating Obesity
DOI:
https://doi.org/10.12775/JEHS.2024.68.49506Keywords
obesity, overweight, bariatric surgery, pharmacotherapy in obesityAbstract
Introduction: In the last few years, obesity has become a central issue with more than 2.6 billion people worldwide being overweight or obese. While the risks associated with this condition and its rising significance are widely known, the effect of this attention on screening and treatment remains unsatisfying. This paper explores multiple treatment strategies and evaluates their effectiveness in preventing obesity-related complications.
Review methods: We conducted our study as a literature review, with data being gathered via PubMed and Embase.
The state of knowledge: Physical activity, behavioral therapy, and proper nutrition remain the foundation for obesity therapy. However, in many cases these approaches are insufficient. Recently, there has been a dynamic development of bariatric surgery and new drugs, which in comparison to lifestyle modification, result in better long-term results and improved quality of life. New surgery procedures, such as sleeve gastrectomy and adjustable gastric banding, have shown to be one of the most effective but still carry a risk of complications. As an alternative pharmacotherapy could be considered with currently used medications including liraglutide, semaglutide, tirzepatide, phentermine-topiramate, orlistat, and bupropion-naltrexone.
Conclusions: Growing treatment options allow physicians to choose more targeted approaches, based on the patient’s risk factors, overall health status, and compliance.
References
World Health Organization. Obesity and overweight; Available from: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight (Accessed: 2024-03-15).
Faccioli N, Poitou C, Clément K, Dubern B. Current Treatments for Patients with Genetic
Obesity. Journal of Clinical Research in Pediatric Endocrinology. 2023;15(2):108-119. https://doi.org/10.4274/jcrpe.galenos.2023.2023-3-2
Bouchard C. Genetics of Obesity: What We Have Learned Over Decades of Research.
Obesity (Silver Spring). 2021;29(5):802-820.
https://doi.org/10.1002/oby.23116
Statista. Obesity Worldwide; Available from: https://www.statista.com/topics/9037/obesity-worldwide/#topicOverview (Accessed: 2024-03-15).
Cornier MA. A review of current guidelines for the treatment of obesity. The American Journal of Managed Care. 2022;28(15 Suppl):S288-S296. https://doi.org/10.37765/ajmc.2022.89292
Ruban A, Stoenchev K, Ashrafian H, Teare J. Current treatments for obesity. Clinical Medicine. 2019;19(3):205-212.
https://doi.org/10.7861/clinmedicine.19-3-205
GBD 2015 Obesity Collaborators; Afshin A, Forouzanfar MH, Reitsma MB, Sur P,. Health Effects of Overweight and Obesity in 195 Countries over 25 Years. New England Journal of Medicine. 2017;377(1):13-27.
https://doi.org/10.1056/NEJMoa1614362
Bhaskaran K, Dos-Santos-Silva I, Leon DA, Douglas IJ, Smeeth L. Association of BMI with overall and cause-specific mortality: a population-based cohort study of 3·6 million adults in the UK. The Lancet Diabetes & Endocrinology. 2018;6(12):944–953.
https://doi.org/10.1016/S2213-8587(18)30288-2
American College of Cardiology/American Heart Association Task Force on Practice Guidelines, Obesity Expert Panel. Expert panel report: Guidelines (2013) for the management of overweight and obesity in adults. Obesity (Silver Spring). 2014;22 Suppl 2:S41–S410.
https://doi.org/10.1002/oby.20660
Apovian CM, Aronne LJ, Bessesen DH, McDonnell ME, Murad MH, Pagotto U, Ryan DH, Still CD, Endocrine Society. Pharmacological management of obesity: an endocrine society clinical practice guideline. Journal of Clinical Endocrinology & Metabolism. 2015;100(2):342–362. Erratum in: J Clin Endocrinol Metab. 2015 May;100(5):2135-6.
https://doi.org/10.1210/jc.2014-3415
Chao AM, Quigley KM, Wadden TA. Dietary interventions for obesity: clinical and mechanistic findings. Journal of Clinical Investigation. 2021;131(1):e140065.
https://doi.org/10.1172/JCI140065
Kim JY. Optimal diet strategies for weight loss and weight loss maintenance. Journal
of Obesity & Metabolic Syndrome. 2021;30(1):20–31.
https://doi.org/10.7570/jomes20065
Smethers AD, Rolls BJ. Dietary management of obesity: Cornerstones of healthy eating patterns. Medical Clinics of North America. 2018;102(1):107–124.
https://doi.org/10.1016/j.mcna.2017.08.009
Thaane T, Motala AA, McKune AJ. Lifestyle modification in the management of insulin resistance states in overweight/obesity: the role of exercise training. Journal of Endocrinology, Metabolism and Diabetes of South Africa. 2019;24(2):65–69.
https://doi.org/10.1080/16089677.2019.1608054
Jacob JJ, Isaac R. Behavioral therapy for management of obesity. Indian Journal of
Endocrinology and Metabolism. 2012;16(1):28-32.
https://doi.org/10.4103/2230-8210.91180
Dalle Grave R, Sartirana M, Calugi S. Personalized cognitive-behavioural therapy for
obesity (CBT-OB): theory, strategies and procedures. Biopsychosocial Medicine. 2020;14:5.
https://doi.org/10.1186/s13030-020-00177-9
Wadden TA, Tronieri JS, Butryn ML. Lifestyle modification approaches for the treatment of obesity in adults. American Psychologist. 2020;75(2):235-251.
https://doi.org/10.1037/amp0000517
Müller T, Finan B, Bloom S, D’Alessio D, Drucker D, Flatt P, et al. Glucagon-like peptide 1 (GLP-1). Molecular Metabolism. 2019;30:72-130.
https://doi.org/10.1016/j.molmet.2019.09.010
Wang JY, Wang QW, Yang XY, Yang W, Li DR, Jin JY, et al. GLP-1 receptor agonists for the treatment of obesity: Role as a promising approach. Frontiers in Endocrinology. 2023;14:1085799.
https://doi.org/10.3389/fendo.2023.1085799
Ranganath LR, Beety JM, Morgan L, Wright J, Howland R, Marks V. Attenuated GLP-1
secretion in obesity: cause or consequence? Gut. 1996;38(6):916-919.
https://doi.org/10.1136/gut.38.6.916
Vrang N, Larsen P. Preproglucagon derived peptides GLP-1, GLP-2 and oxyntomodulin in the CNS: Role of peripherally secreted and centrally produced peptides. Progress in Neurobiology. 2010;92:442-462.
https://doi.org/10.1016/j.pneurobio.2010.07.003
]Larsen PJ, Vrang N, Tang-Christensen M. Central pre-proglucagon derived peptides: Opportunities for treatment of obesity. Current Pharmaceutical Design. 2003;9:1373–1382.
https://doi.org/10.2174/1381612033454775
Sirohi S, Schurdak J, Seeley R, Benoit S, Davis J. Central & peripheral glucagon-like peptide-1 receptor signaling differentially regulate addictive behaviors. Physiology and Behavior. 2016;161:140-144.
https://doi.org/10.1016/j.physbeh.2016.04.013
Decarie-Spain L, Fisette A, Zhu Z, Yang B, DiMarchi R, Tschöp M. GLP-1/dexamethasone inhibits food reward without inducing mood and memory deficits in mice. Neuropharmacology. 2019;151:55–63.
https://doi.org/10.1016/j.neuropharm.2019.03.035
FDA approves new drug treatment for chronic weight management for first time in 14 years.https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-treatment-chronic-weight-management-first-2014. Accessed: 2024-01-28.
O’Neil P, Birkenfeld A, McGowan B, Mosenzon O, Pedersen S, Wharton S, et al. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. Lancet. 2018;392:637-649.
https://doi.org/10.1016/S0140-6736(18)31773-2
Kelly A, Auerbach P, Barrientos-Perez M, Gies I, Hale P, Marcus C, et al. A randomized,
controlled trial of liraglutide for adolescents with obesity. The New England Journal of Medicine. 2020;382:2117-2128.
https://doi.org/10.1056/NEJMoa1916038
Ladenheim E. Liraglutide and obesity: a review of the data so far. Drug Design, Development and Therapy. 2015;9:1867-1875.
https://doi.org/10.2147/DDDT.S58459
Saxenda: highlights of prescribing information. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/206321s025lbl.pdf. (Accessed 2024-03-14).
Saxenda: summary of product characteristics [Internet]. Available from: https://www.ema.europa.eu/en/documents/product-information/saxenda-epar-product-information_en.pdf. (Accessed 2024-03-14).
Weghuber D, Barrett T, Barrientos-Pérez M, Gies I, Hesse D, Jeppesen O, et al. Once-weekly semaglutide in adolescents with obesity. The New England Journal of Medicine. 2022;386:233-44.
https://doi.org/10.1056/NEJMoa1916038
Rubino D, Greenway F, Khalid U, O’Neil P, Rosenstock J, Sørrig R, et al. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: The step 8 randomized clinical trial. Journal of the American Medical Association. 2021;326:1925-1935.
https://doi.org/10.1001/jama.2021.23619
Shin JH, Gadde KM. Clinical utility of phentermine/topiramate (Qsymia™) combination
for the treatment of obesity. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy. 2013;6:131-139.
https://doi.org/10.2147/DMSO.S43403
Coulter AA, Rebello CJ, Greenway FL. Centrally acting agents for obesity: Past, present, and future. Drugs. 2018;78(11):1113-1132.
https://doi.org/10.1007/s40265-018-0946-y
Lewis KH, Fischer H, Ard J, Barton L, Bessesen DH, Daley MF, et al. Safety and effectiveness of longer-term phentermine use: Clinical outcomes from an electronic health record cohort. Obesity (Silver Spring). 2019;27(4):591–602.
https://doi.org/10.1002/oby.22430
Son JW, Kim SK. Comprehensive review of current and upcoming anti-obesity drugs. Diabetes & Metabolism Journal. 2020;44(6):802–818.
https://doi.org/10.4093/dmj.2020.0258
Aronne LJ, Wadden TA, Peterson C, Winslow D, Odeh S, Gadde KM. Evaluation of phentermine and topiramate versus phentermine/topiramate extended-release in obese adults. Obesity (Silver Spring). 2013;21(11):2163-2171.
https://doi.org/10.1002/oby.20584
Gadde KM, Allison DB, Ryan DH, Peterson CA, Troupin B, Schwiers ML, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. The Lancet. 2011;377(9774):1341-1352. Erratum in: Lancet. 2011 Apr 30;377(9776):1494.
https://doi.org/10.1016/S0140-6736(11)60205-5
Smith SM, Meyer M, Trinkley KE. Phentermine/topiramate for the treatment of obesity. Annals of Pharmacotherapy. 2013;47(3):340–9.
https://doi.org/10.1345/aph.1R501
Grewal DS, Goldstein DA, Khatana AK, Tanna AP. Bilateral angle closure following use of a weight loss combination agent containing topiramate. Journal of Glaucoma. 2015 June/July;24(5):e132–e136.
https://doi.org/10.1097/IJG.0000000000000157
Davidson MH, Tonstad S, Oparil S, Schwiers M, Day WW, Bowden CH. Changes in cardiovascular risk associated with phentermine and topiramate extended-release in participants with comorbidities and a body mass index 27 kg/m(2). The American Journal of Cardiology. 2013;111(8):1131-1138.
https://doi.org/10.1016/j.amjcard.2012.12.038
Heck AM, Yanovski JA, Calis KA. Orlistat, a new lipase inhibitor for the management of obesity. Pharmacotherapy. 2000 Mar;20(3):270-279.
https://doi.org/10.1592/phco.20.4.270.34882
Hadváry P, Lengsfeld H, Wolfer H. Inhibition of pancreatic lipase in vitro by the covalent inhibitor tetrahydrolipstatin. Biochemical Journal. 1988 Dec;256(2):357-361.
https://doi.org/10.1042/bj2560357
Moreau H, Moulin A, Gargouri Y, Noël J, Verger R. Inactivation of gastric and pancreatic lipases by diethyl p-nitrophenyl phosphate. Biochemistry. 1991 Jan;30(4):1037–1041.
https://doi.org/10.1021/bi00218a022
Zhi J, Melia A, Funk C, Viger-Chougnet A, Hopfgartner G, Lausecker B, Wang K, Fulton J, Gabriel L, Mulligan T. Metabolic profiles of minimally absorbed orlistat in obese/overweight volunteers. The Journal of Clinical Pharmacology. 1996 Nov;36(11):1006–1011.
https://doi.org/10.1177/009127009603601104
Zhi J, Melia A, Guerciolini R, Chung J, Kinberg J, Hauptman J, Patel I. Retrospective population-based analysis of the dose-response (fecal fat excretion) relationship of orlistat in normal and obese volunteers. Clinical Pharmacology & Therapeutics. 1994 Jul;56(1):82–85.
https://doi.org/10.1038/clpt.1994.104
Khera R, Murad MH, Chandar AK, Dulai PS, Wang Z, Prokop LJ, Loomba R, Camilleri M, Singh S. Association of pharmacological treatments for obesity with weight loss and adverse events: A systematic review and meta-analysis. Journal of the American Medical Association. 2016 Jun;315(22):2424–2434.
https://doi.org/10.1001/jama.2016.7602
Sahebkar A, Simental-Mendía LE, Reiner Ž, Kovanen PT, Simental-Mendía M, Bianconi V, Pirro M. Effect of orlistat on plasma lipids and body weight: A systematic review and meta-analysis of 33 randomized controlled trials. Pharmacological Research. 2017 Aug;122:53–65.
https://doi.org/10.1016/j.phrs.2017.05.022
Damci T, Yalin S, Balci H, Osar Z, Korugan U, Ozyazar M, Ilkova H. Orlistat augments postprandial increases in glucagon-like peptide 1 in obese type 2 diabetic patients. Diabetes Care. 2004 May;27(5):1077–1080.
https://doi.org/10.2337/diacare.27.5.1077
Jacob S, Rabbia M, Meier M, Hauptman J. Orlistat 120 mg improves glycaemic control in type 2 diabetic patients with or without concurrent weight loss. Diabetes, Obesity and Metabolism. 2009 Apr;11(4):361–371.
https://doi.org/10.1111/j.1463-1326.2008.00970.x
Hauptman J, Lucas C, Boldrin M, Collins H, Segal K. Orlistat in the long-term treatment of obesity in primary care settings. Archives of Family Medicine. 2000 Feb;9(2):160–167.
https://doi.org/10.1001/archfami.9.2.160
Davidson M, Hauptman J, DiGirolamo M, Foreyt J, Halsted C, Heber D, Heimburger D, Lucas C, Robbins D, Chung J, Heymsfield S. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION. 1999 Jan;281(3):235–242.
https://doi.org/10.1001/jama.281.3.235
Fujioka K. Current and emerging medications for overweight or obesity in people with comorbidities. Diabetes, Obesity and Metabolism. 2015 Nov;17(11):1021–1032.
https://doi.org/10.1111/dom.12502
Filippatos T, Derdemezis C, Gazi I, Nakou E, Mikhailidis D, Elisaf M. Orlistat-associated adverse effects and drug interactions: a critical review. Drug Safety. 2008 Jan;31(1):53–65.
https://doi.org/10.2165/00002018-200831010-00005
Beyea M, Garg A, Weir M. Does orlistat cause acute kidney injury? Therapeutic Advances in Drug Safety. 2012 Apr;3(2):53–57.
https://doi.org/10.1177/2042098611429985
Kose M, Emet S, Akpinar T, Ilhan M, Gok A, Dadashov M, Tukek T. An unexpected result of obesity treatment: Orlistat-related acute pancreatitis. Case Reports in Gastroenterology. 2015 May;9(2):152–155.
https://doi.org/10.1159/000430433
Ahmad FA, Mahmud S. Acute pancreatitis following orlistat therapy: report of two cases. Journal of the pancreas. 2010 Jan;11(1):61–63.
Napier S, Thomas M. 36 year old man presenting with pancreatitis and a history of recent commencement of orlistat case report. Nutrition Journal. 2006 Aug;5:19.
https://doi.org/10.1186/1475-2891-5-19
Huecker M, Smiley A, Saadabadi A. Bupropion. StatPearls. 2023. Available from: https://www.ncbi.nlm.nih.gov/books/NBK547668/ (Accessed: 2024-03-15)
Hillemacher T, Heberlein A, Muschler MA, Bleich S, Frieling H. Opioid modulators for alcohol dependence. Expert Opinion on Investigational Drugs. 2011;20(8):1073–1086.
https://doi.org/10.1517/13543784.2011.592139
Caixàs A, Albert L, Capel I, Rigla M. Naltrexone sustained-release/bupropion sustained-release for the management of obesity: review of the data to date. Drug Design, Development and Therapy. 2014;8:1419–1427.
https://doi.org/10.2147/DDDT.S55587
Wang G, Tomasi D, Volkow N, Wang R, Telang F, Caparelli E, Dunayevich E. Effect of combined naltrexone and bupropion therapy on the brain's reactivity to food cues International Journal of Obesity (Lond). 2014;38(5):682–688.
https://doi.org/10.1038/ijo.2013.145
Apovian C, Aronne L, Rubino D, Still C, Wyatt H, Burns C, Kim D, Dunayevich E, C.-I. S. Group. A randomized, phase 3 trial of naltrexone sr/bupropion sr on weight and obesity-related risk factors (cor-ii). Obesity (Silver Spring). 2013;21(5):935–943.
https://doi.org/10.1002/oby.20309
Hollander P, Gupta A, Plodkowski R, Greenway F, Bays H, Burns C, Klassen P, Fujioka K, C.-D. S. Group. Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. Diabetes Care. 2013;36(12):4022–4029.
https://doi.org/10.2337/dc13-0234
Onakpoya I, Lee J, Mahtani K, Aronson J, Heneghan C. Naltrexone-bupropion (mysimba) in management of obesity: A systematic review and meta-analysis of unpublished clinical study reports. British Journal of Clinical Pharmacology. 2020;86(4):646–667.
https://doi.org/10.1111/bcp.14210
Nauck MA, Meier JJ. Incretin hormones: Their role in health and disease. Diabetes, Obesity and Metabolism. 2018;20(Suppl 1):5–21.
https://doi.org/10.1111/dom.13129
Syed YY. Tirzepatide: First approval. Drugs. 2022;82(11):1213–20.
https://doi.org/10.1007/s40265-022-01746-8
Abbasi J. FDA green-lights tirzepatide, marketed as zepbound, for chronic weight management. JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION. 2023;330(22):2143–2144.
https://doi.org/10.1001/jama.2023.24539
Rosenstock J, Wysham C, Frías JP, Kaneko S, Lee CJ, Fernández Landó L, Mao H, Cui X, Karanikas CA, Thieu VT. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): A double-blind, randomised, phase 3 trial. Lancet. 2021;398(10295):143–155.
https://doi.org/10.1016/S0140-6736(21)01324-6
Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A. Tirzepatide once weekly for the treatment of obesity. The New England Journal of Medicine. 2022;387(3):205–216.
https://doi.org/10.1056/NEJMoa2206038
Garvey WT, Frias JP, Jastreboff AM, le Roux CW, Sattar N, Aizenberg D, Mao H, Zhang S, Ahmad NN, Bunck MC, Benabbad I, Zhang X. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): A double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2023;402(10402):613–626.
https://doi.org/10.1016/S0140-6736(23)01200-X
Wadden TA, Chao AM, Machineni S, Kushner R, Ard J, Srivastava G, Halpern B, Zhang S, Chen J, Bunck MC, Ahmad NN, Forrester T. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: The SURMOUNT-3 phase 3 trial. Nature Medicine. 2023;29(11):2909–2918.
https://doi.org/10.1038/s41591-023-02597-w
Arterburn DE, Courcoulas AP. Bariatric surgery for obesity and metabolic conditions in adults. BMJ. 2014;349:g3961.
https://doi.org/10.1136/bmj.g3961
Keyte R, Mantzios M, Hussain M, et al. ‘surgery is my only hope’: A qualitative study exploring perceptions of living with obesity and the prospect of having bariatric surgery. Clinical Obesity. 2024.
https://doi.org/10.1111/cob.12643
Arterburn DE, Olsen MK, Smith VA, et al. Association between bariatric surgery and long-term survival. JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION. 2015;313:62–70.
https://doi.org/10.1001/jama.2014.16968
Balsiger BM, Murr MM, Poggio JL, Sarr MG. Bariatric surgery. Surgery for weight control in patients with morbid obesity. Medical Clinics of North America. 2000;84(2):477–489.
https://doi.org/10.1016/s0025-7125(05)70232-7
Welbourn R, Dixon J, Barth JH, et al. NICE-accredited commissioning guidance for weight assessment and management clinics: a model for a specialist multidisciplinary team approach for people with severe obesity. Obesity Surgery. 2016;26:649–59.
https://doi.org/10.1007/s11695-015-2041-8
Moshiri M, Osman S, Robinson TJ, Khandelwal S, Bhargava P, Rohrmann CA. Evolution of bariatric surgery: a historical perspective. AJR. American journal of roentgenology. 2013;201(1):W40–48.
https://doi.org/10.2214/AJR.12.10131
Buchwald H, Oien DM. Metabolic/bariatric surgery worldwide 2011. Obesity Surgery. 2013;23:427–436.
https://doi.org/10.1007/s11695-012-0864-0
Colquitt J, Pickett K, Loveman E, Frampton GK. Surgery for weight loss in adults. Cochrane Database of Systematic Reviews. 2014;(8).
https://doi.org/10.1002/14651858.CD003641.pub4
Carucci LR, Turner MA. Imaging following bariatric procedures: Roux-en-Y gastric bypass, gastric sleeve, and biliopancreatic diversion. Abdominal Imaging. 2012 Oct;37(5):697–711.
https://doi.org/10.1007/s00261-012-9860-z
Baltasar A, Bou R, Miro J, Bengochea M, Serra C, Perez N. Laparoscopic biliopancreatic diversion with duodenal switch: technique and initial experience. Obesity Surgery. 2002;12:245–248.
https://doi.org/10.1381/096089202762552430
Jones KJ. Bariatric surgery–where do we go from here? International Surgery. 2004 Jan-Mar;89(1):51–57.
Brajcich BC, Hungness ES. Sleeve gastrectomy. Journal of the American Medical Association. 2020;324(9):908.
https://doi.org/10.1001/jama.2020.14775
McGuire MM, Nadler EP, Qureshi FG. Laparoscopic vertical sleeve gastrectomy for adolescents with morbid obesity. Seminars in Pediatric Surgery. 2014;23(1):21–23.
https://doi.org/10.1053/j.sempedsurg.2013.10.021
Hutter MM, Schirmer BD, Jones DB, Ko CY, Cohen ME, Merkow RP, Nguyen NT. First report from the American College of Surgeons Bariatric Surgery Center Network: laparoscopic sleeve gastrectomy has morbidity and effectiveness positioned between the band and the bypass. Annals of Surgery. 2011 Sep;254(3):410–420, discussion 420-422.
https://doi.org/10.1097/SLA.0b013e31823059e9
National Center for Biotechnology Information (US). Principles of nutrition and nutritional assessment. 2022. Available from: https://www.ncbi.nlm.nih.gov/books/NBK553157/ (Accessed 2024-03-15)
Suter M, Giusti V, Héraief E, Zysset F, Calmes JM. Laparoscopic Roux-en-Y gastric bypass: initial 2-year experience. Surgical Endoscopy. 2003;17(4):603–609.
https://doi.org/10.1007/s00464-002-8952-1
Sarabu N. Weight and metabolic outcomes 12 years after gastric bypass. New England Journal of Medicine. 2018;378(1):93–94.
https://doi.org/10.1056/NEJMc1714001
Hachem A, Brennan L. Quality of life outcomes of bariatric surgery: A systematic review. Obesity Surgery. 2016;26(2):395–409.
https://doi.org/10.1007/s11695-015-1940-z
Chang H, Stoll RT, Song J, Varela JE, Eagon JC, Colditz GA. Bariatric surgery: An updated systematic review and meta-analysis, 2003–2012. JAMA Surgery. 2014;149(3):275.
https://doi.org/10.1001/jamasurg.2013.3654
Lee C, Kelly J, Wassef W. Complications of bariatric surgery. Current Opinion in Gastroenterology. 2007;23:636–643.
Monkhouse S, Morgan J, Norton S. Complications of Bariatric Surgery: Presentation and Emergency Management – a Review. Annals of The Royal College of Surgeons of England. 2009;91(4):280-286.
https://doi.org/10.1308/003588409X392072
Guadalajara H, Sanz Baro R, Pascual I, Blesa I, Rotundo GS, et al. Is prophylactic cholecystectomy useful in obese patients undergoing gastric bypass? Obesity Surgery. 2006;16:883–885.
https://doi.org/10.1381/096089206777822287
Sapala JA, Wood MH, Schuhknecht MP, Sapala MA. Fatal pulmonary embolism after bariatric operations for morbid obesity: a 24-year retrospective analysis. Obesity Surgery. 2003;13(6):819-825.
https://doi.org/10.1381/096089203322618588
Bal BS STKT Finelli FC. Nutritional deficiencies after bariatric surgery. Nature Reviews Endocrinology. 2012;Sep;8(9):544-556.
https://doi.org/10.1038/nrendo.2012.48
Prykhodko O CMIBZTLUHF, Burleigh S. Long-Term Changes to the Microbiome, Blood Lipid Profiles and IL-6 in Female and Male Swedish Patients in Response to Bariatric Roux-en-Y Gastric Bypass. Nutrients. 2024;Feb 9;16(4):498.
https://doi.org/10.3390/nu16040498
Crossan K, Sheer A. Intragastric Balloon. StatPearls. 2023 Jan.
https://doi.org/10.1186/s43044-021-00319-1
Abu Dayyeh B. Intragastric Balloons for Obesity Management. Gastroenterology and Hepatology (NY). 2017;13(12):737-739.
Stanford F, Kyle T, Claridy M, Nadglowski J, Apovian C. The influence of an individual’s weight perception on the acceptance of bariatric surgery. Obesity (Silver Spring). 2015;23(2):277-281.
https://doi.org/10.1002/oby.20968
Göttig S, Weiner R, Daskalakis M. Preoperative weight reduction using the intragastric balloon. Obesity Facts. 2009;2(Suppl 1):20-23.
https://doi.org/10.1159/000198243
Kumar N. Endoscopic therapy for weight loss: Gastroplasty, duodenal sleeves, intragastric balloons, and aspiration. World J Gastrointest Endosc. 2015;7(9):847-859.
https://doi.org/10.4253/wjge.v7.i9.847
Fernandes M, Atallah A, Soares B, Humberto S, Guimarães S, Matos D, et al. Intragastric balloon for obesity. The Cochrane Database of Systematic Reviews. 2007;2007(1):CD004931.
https://doi.org/10.1002/14651858.CD004931.pub2
Gollisch K, Raddatz D. Endoscopic intragastric balloon: a gimmick or a viable option for obesity? Annals of Translational Medicine. 2020;8(Suppl 1):S8.
https://doi.org/10.21037/atm.2019.09.67
Choi S, Choi H. Various Intragastric Balloons Under Clinical Investigation. Clinical Endoscopy. 2018;51(5):407-415.
https://doi.org/10.5946/ce.2018.140
Cummings D, Purnell J, Frayo R, Schmidova K, Wisse B, Weigle D. A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes. 2001;50(8):1714-1719.
https://doi.org/10.2337/diabetes.50.8.1714
Phillips R, Powley T. Gastric volume rather than nutrient content inhibits food intake. American Journal of Physiology. 1996;271(3 Pt 2):R766-769.
https://doi.org/10.1152/ajpregu.1996.271.3.R766
Bazerbachi F, Vargas E, Abu Dayyeh B. Endoscopic Bariatric Therapy: A Guide to the Intragastric Balloon. American Journal of Gastroenterology. 2019;114(9):1421-1431.
https://doi.org/10.14309/ajg.0000000000000239
Kumar N, Sullivan S, Thompson C. The role of endoscopic therapy in obesity management: intragastric balloons and aspiration therapy. Diabetes Metabolic Syndrome and Obesity. 2017;10:311-316.
https://doi.org/10.2147/DMSO.S95118
Abu Dayyeh B, Kumar N, Edmundowicz S, et al. ASGE Bariatric Endoscopy Task Force. ASGE Technology Committee ASGE bariatric endoscopy task force systematic review and meta-analysis assessing the ASGE PIVI thresholds for adopting endoscopic bariatric therapies. Gastrointestinal Endoscopy. 2015;82(3):425-438.
https://doi.org/10.1016/j.gie.2015.03.1964
Ponce J, Woodman G, Swain J, et al. The reduce pivotal trial: a prospective, randomized controlled pivotal trial of a dual intragastric balloon for the treatment of obesity. Surgery for Obesity and Related Diseases. 2015;11(4):874-881.
https://doi.org/10.1016/j.soard.2014.12.006
Sullivan S, Swain J, Woodman G. Randomized sham-controlled trial of the 6-month swallowable gas-filled intragastric balloon system for weight loss. Surgery for Obesity and Related Diseases. 2018;14(12):1876-1889.
https://doi.org/10.1016/j.soard.2018.09.486
Machytka E, Klvana P, Kornbluth A. Adjustable Intragastric Balloons: A 12-Month Pilot Trial in Endoscopic Weight Loss Management. Obesity Surgery. 2011;21(10):1499–1507.
https://doi.org/10.1007/s11695-011-0424-z
Brooks J, Srivastava E, Mathus-Vliegen E. One-Year Adjustable Intragastric Balloons: Results in 73 Consecutive Patients in the U.K. Obesity Surgery. 2014;24(5):813–819.
https://doi.org/10.1007/s11695-014-1176-3
Machytka E, Brooks J, Buzga M, Mason J. One Year Adjustable Intragastric Balloon: Safety and Efficacy of the Spatz3 Adjustable Balloons. F1000Research. 2014;3:203.
https://doi.org/10.12688/f1000research.5099.1
Lari E, Burhamah W, Lari A, Alsaeed T, Al-Yaqout K, Al-Sabah S. Intra-gastric Balloons - The Past, Present and Future. Annals of Medicine and Surgery (Lond). 2021 Feb 2;63:102138.
https://doi.org/10.1016/j.amsu.2021.01.086
Jacob S, Nair AB, Shah J, Sreeharsha N, Gupta S, Shinu P. Emerging Role of Hydrogels in Drug Delivery Systems, Tissue Engineering and Wound Management. Pharmaceutics. 2021;13(3):357.
https://doi.org/10.3390/pharmaceutics13030357
Fu LH, Qi C, Ma MG, Wan P. Multifunctional cellulose-based hydrogels for biomedical applications. Journal of Materials Chemistry B. 2019;7(10):1541-1562.
https://doi.org/10.1039/c8tb02331j
Calo E, Khutoryanskiy VV. Biomedical applications of hydrogels: a review of patents and commercial products. European Polymer Journal. 2015;65:252-267
https://doi.org/10.1016/j.eurpolymj.2014.11.024
Aronne LJ, Anderson JE, Sannino A, Chiquette E. Recent advances in therapies utilizing superabsorbent hydrogel technology for weight management: A review. Obesity Science & Practice. 2021;8(3):363-370.
https://doi.org/10.1002/osp4.574
Sannino A, Demitri C, Madaghiele M. Biodegradable cellulose-based hydrogels: design and applications. Materials. 2009;2(2):353-373.
https://doi.org/10.3390/ma2020353
Greenway FL, Aronne LJ, Raben A, Astrup A, Apovian CM, Hill JO, et al. A Randomized, Double-Blind, Placebo-Controlled Study of Gelesis100: A Novel Nonsystemic Oral Hydrogel for Weight Loss. Obesity (Silver Spring). 2019;27(2):205-216. Erratum in: Obesity (Silver Spring). 2019 Apr;27(4):679. Erratum in: Obesity (Silver Spring). 2019 Jul;27(7):1210.
https://doi.org/10.1002/oby.22347
Madaghiele M, Demitri C, Surano I, Silvestri A, Vitale M, Panteca E, et al. Biomimetic cellulose-based superabsorbent hydrogels for treating obesity. Scientific Reports. 2021;11(1):21394. Erratum in: Scientific Reports. 2021 Dec 29;11(1):24533.
https://doi.org/10.1038/s41598-021-00884-5
Phillips RJ, Powley TL. Tension and stretch receptors in gastrointestinal smooth muscle: re-evaluating vagal mechanoreceptor electrophysiology. Brain Research Brain Research Reviews. 2000;34:1-26.
https://doi.org/10.1016/s0165-0173(00)00036-9
Janssen P, Vanden Berghe P, Verschueren S, Lehmann A, Depoortere I, Tack J. Review article: the role of gastric motility in the control of food intake. Alimentary Pharmacology & Therapeutics. 2011;33:880-894.
https://doi.org/10.1111/j.1365-2036.2011.04609.x
Liu X, Steiger C, Lin S, Parada GA, Liu J, Chan HF, et al. Ingestible hydrogel device. Nature Communications. 2019;10(1):493.
https://doi.org/10.1038/s41467-019-08355-2
Raman R, Hua T, Gwynne D, et al. Light-degradable hydrogels as dynamic triggers for gastrointestinal applications. Science Advances. 2020;6.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Aleksandra Jędrasek, Marta Barg, Julia Biały-Karbowniczek, Agata Bartela, Klaudia Wojtyła
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 380
Number of citations: 0
